Results that are unfavourable to the sponsor—that
is, trials that find a drug is less clinically effective or cost
effective or less safe than other drugs used to treat the
same condition—can pose considerable financial risks
to companies. Pressure to show that the drug causes a
favourable outcome may result in biases in design, outcome,
and reporting of industry sponsored research.